Table 1 Clinical characteristics of AML patients and controls.
From: Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia
Clinical characteristics | ND AML patients (n = 58) | CR AML patients (n = 57) | Controls (n = 15) |
|---|---|---|---|
Age (years, median, range) | 43 (18–83) | 40 (18–66) | 39 (18–67) |
Sex (male/female) | 25/33 | 31/26 | 5/10 |
WBC (×109/L) | 42.51 ± 50.67 | 5.00 ± 2.40 | 5.50 ± 3.40 |
RBC (×1012/L) | 2.44 ± 0.84 | 3.88 ± 0.86 | 3.93 ± 0.76 |
HGB (g/L) | 78.79 ± 23.57 | 120.12 ± 26.44 | 121.32 ± 20.34 |
PLT (×109/L) | 60.98 ± 78.48 | 245.25 ± 124.15 | 255.25 ± 144.65 |
BM leukemic blasts (%) | 79.81 ± 19.42 | 1.76 ± 0.68 |  |
Abnormal karyotype (n, %) | 16 (42%) | 15 (75%) | Â |
FAB classification | |||
   M1 | 2 | 0 |  |
   M2 | 2 | 7 |  |
   M3 | 13 | 40 |  |
   M4 | 7 | 3 |  |
   M5 | 28 | 7 |  |
   unclassified | 6 | 0 |  |
